Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Ocugen, Inc.

Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocugen reports progress in gene therapy trials amidst financial stability

Ocugen's Q1 2024 performance reflects a mix of financial stability and regulatory milestones.
The company's strengths lie in its promising gene therapy platform and efficient cost management.
Challenges include timeline pressures for upcoming trial updates and ongoing financial constraints.
Opportunities arise from market expansion potential, investor confidence, and strategic partnerships.

Ocugen reports strong Q3 progress with key approvals and financial stability

Ocugen's Q3 2024 earnings call highlighted notable achievements in clinical advancements, regulatory approvals, and financial stability, positioning the company for future growth.
With a focus on advancing key pipeline candidates and managing expenses effectively, Ocugen aims to capitalize on opportunities for expansion and partnership collaborations.
While facing challenges in meeting timelines and ensuring successful trial outcomes, Ocugen remains optimistic about the potential of its innovative therapies to address unmet medical needs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Topline data anticipated in second half of 2020 Topline data anticipated in second half of 2020

Ocugen Announces Completion of 50% of Enrollment of its Phase 3 Clinical Trial for ocular GVHD

How Ocugen stock came to be makes no sense. Neither does the idea that investors will continue to pour money into this cesspool.

With No Revenue or Approved Treatments, Ocugen Stock Is a Clear Sell

Since Ocugen completed its merger with Histogenics Sept. 30, Ocugen stock has lost 85% of its value.

There’s a Better Way to Play Ocugen Stock

Ocugen gave rise to OCGN stock through a reverse merger with Histogenics. But despite this confusing deal, it really didn't do much for either company in the end.

Ocugen Stock Is Nothing More than a Risky Trade on Even-riskier Biotech

Ocugen, Inc. (OCGN) CEO Shankar Musunuri on Q3 2019 Results - Earnings Call Transcript

Reduced Series C warrant shares to 20 million from 50 million Reduced Series C warrant shares to 20 million from 50 million

Ocugen Announces Warrant Restructuring

MALVERN, Pa., Nov.  04, 2019  (GLOBE NEWSWIRE) --  Ocugen, Inc. , (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of retina and ocular Graft-Versus-Host Disease (oGVHD) scientific advisory boards comprised of prominent experts to provide strategic advice, clinical and regulatory support, and scientific and industry expertise.

Ocugen Announces Appointments to Retina Disease and Ocular Graft-Versus-Host Disease Scientific Advisory Boards

MALVERN, Pa., Oct.  23, 2019  (GLOBE NEWSWIRE) --  Ocugen, Inc. , (NASDAQ: OCGN), a clinical stage biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases, today announced the appointment of Jessica Crespo, CPA, to the role of Controller, effective October 23, 2019.

Ocugen Appoints Jessica Crespo, CPA, as Controller

Ocugen (OCGN) news for Wednesday about a massive stock buyback plan for $2 million worth of shares has OCGN stock on the move.

Ocugen News: OCGN Stock Soars 40% on Stock Buyback Plan

News for Ocugen, Inc. Stock (OCGN)